Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: CRL

Charles River Laboratories International, Inc.

Healthcare | Medical - Diagnostics & Research
$230.69 +65.58 (+39.71%) as of 2026-07-15 04:49 UTC
Market Cap$11.1B
Volume736.8K
EPS (TTM)$-2.91

Charles River Laboratories International, Inc. (NYSE: CRL) is a $11.1B medical - diagnostics & research company trading at $230.69 (+39.7% today). Figures from SEC EDGAR and market feeds; updated 2026-07-15 04:49 UTC.

52-Week Range
Low $164.44High $231.46

What Charles River Laboratories International, Inc. does

Charles River Laboratories International, Inc. began operating in 1947 and was incorporated in 1994, completing its initial public offering in 2000. The company is headquartered in Wilmington, Massachusetts, and its stock trades on the New York Stock Exchange under the symbol CRL, with inclusion in major indices including the Standard & Poor's 500. The company operates in the drug discovery and development services sector, providing outsourced services to pharmaceutical and biotechnology companies.

Summarized from Charles River Laboratories International, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$230.69
Change (1D)+65.58 (+39.71%)
Market cap$11.1B
Volume736.8K shares
52-week range$164.44 – $231.46
Valuation
EPS (TTM)$-2.91
Price/book3.50×
Returns
52-week return+40.3%
Revenue, margins & earnings
FY2021 Net income: $399MFY2021 Taxes & interest: $191MFY2021 Operating costs: $2.95B$3.54BFY2021FY2022 Net income: $493MFY2022 Taxes & interest: $158MFY2022 Operating costs: $3.33B$3.98BFY2022FY2023 Net income: $480MFY2023 Taxes & interest: $137MFY2023 Operating costs: $3.51B$4.13BFY2023FY2024 Taxes & interest: $202MFY2024 Operating costs: $3.82B$4.05BFY2024FY2025: net loss $142M on revenue $4.02B$4.02BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-01
  • 2026-07-01FOSTER JAMES CSELL-75,000$16.88M
  • 2026-06-08FOSTER JAMES CG-153,361—
  • 2026-06-08FOSTER JAMES CG153,361—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC5,729,800$1.14B-1.9%
  • FMR LLC3,427,822$591.30M+97.7%
  • VANGUARD CAPITAL MANAGEMENT LLC3,202,204$552.38MNEW
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Charles River Laboratories International, Inc. do?

Charles River Laboratories International, Inc.

What is CRL's valuation?

CRL trades at $230.69, as of 2026-07-15.

When did CRL last file with the SEC?

Charles River Laboratories International, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 04:49 UTC. This page is also available as JSON at /api/data?ticker=CRL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CRL and 3,500+ tickers.

Create a free account — keep CRL
For your agent
GET /api/data?ticker=CRL

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt